

Disclaimers

This presentation provides relevant information about SoftBank Group Corp. (“SBG”) and its subsidiaries (together with SBG, the “Company”) and its affiliates (together with the Company, the “Group”) and does not constitute or form any solicitation of investment including any offer to buy or subscribe for any securities in any jurisdiction.

This presentation contains forward-looking statements, beliefs or opinions regarding the Group, such as statements about the Group’s future business, future position and results of operations, including estimates, forecasts, targets and plans for the Group. Without limitation, forward-looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this presentation are based on the current assumptions and beliefs of the Group in light of the information currently available to it as of the date hereof. Such forward-looking statements do not represent any guarantee by any member of the Group or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the success of the Group’s business model; the Group’s ability to procure funding and the effect of its funding arrangements; key person risks relating to the management team of SBG; risks relating to and affecting the Group’s investment activities; risks relating to SB Fund (defined as below), its investments, investors and investees; risks relating to SoftBank Corp. and the success of its business; risks relating to law, regulation and regulatory regimes; risks relating to intellectual property; litigation; and other factors, any of which may cause the Group’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect the Group’s results, performance, achievements, or financial position, see “Risk Factors” on SBG’s website at https://group.softbank/en/ir/investors/management_policy/risk_factor. None of the Group nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance, achievements or financial position could materially differ from expectations. Persons viewing this presentation should not place undue reliance on forward looking statements. The Company undertakes no obligation to update any of the forward-looking statements contained in this presentation or any other forward-looking statements the Company may make. Past performance is not an indicator of future results and the results of the Group in this presentation may not be indicative of, and are not an estimate, forecast or projection of the Group’s future results.

The Company does not guarantee the accuracy or completeness of information in this presentation regarding companies (including, but not limited to, those in which SB Funds have invested) other than the Group which has been quoted from public and other sources.

Regarding Trademarks

Names of companies, products and services that appear in this presentation are trademarks or registered trademarks of their respective companies.

Important Notice – Trading of SBG Common Stock, Disclaimer Regarding Un-sponsored American Depository Receipts


SBG encourages anyone interested in buying or selling its common stock to do so on the Tokyo Stock Exchange, which is where its common stock is listed and primarily trades. SBG’s disclosures are not intended to facilitate trades in, and should not be relied on for decisions to trade, un-sponsored American Depository Receipts (“ADRs”).

SBG has not and does not participate in, support, encourage, or otherwise consent to the creation of any un-sponsored ADR programs or the issuance or trading of any ADRs issued thereunder in respect of its common stock. SBG does not represent to any ADR holder, bank or depository institution, nor should any such person or entity form the belief, that (i) SBG has any reporting obligations within the meaning of the U.S. Securities Exchange Act of 1934 (“Exchange Act”) or (ii) SBG’s website will contain on an ongoing basis all information necessary for SBG to maintain an exemption from registering its common stock under the Exchange Act pursuant to Rule 12g3-2(b) thereunder.

To the maximum extent permitted by applicable law, SBG and the Group disclaim any responsibility or liability to ADR holders, banks, depository institutions, or any other entities or individuals in connection with any un-sponsored ADRs representing its common stock.

The above disclaimers apply with equal force to the securities of any of the Group which are or may in the future be the subject of un-sponsored ADR programs, such as SoftBank Corp. or LY Corporation.





A photograph of a person lying in a hospital bed, viewed through the metal bed rails. The person is wearing a blue hospital gown and has their right hand resting on a white blanket. A clear plastic IV drip is attached to their hand, secured with white tape. The background is slightly blurred, showing the hospital room environment. The word "Sadness" is overlaid in white serif font across the center of the image.

Sadness




14 Years Ago

2010.6.25

New 30-Year Vision



**What is the
saddest thing in
life?**



Causes of Death in Japan


2010

1	Malignant Neoplasm (Cancer)
2	Cardiovascular Disease
3	Cerebrovascular Disease
4	Pneumonia
5	Traffic Accidents

Causes of Death in Japan

2010


1	Malignant Neoplasm (Cancer)
2	Cardiovascular Disease
3	Cerebrovascular Disease
4	Pneumonia
5	Traffic Accidents



2023年

1	Malignant Neoplasm (Cancer)
2	Cardiovascular Disease
3	Die of old age
4	Cerebrovascular Disease
5	Pneumonia


Cancer is always a cause of sorrow for many.

A woman with long dark hair, wearing a blue hospital gown, is sitting on a chair next to a hospital bed. She is looking towards the bed with a distressed expression, her hands clasped near her face. The patient in the bed is partially visible, lying under a white blanket. The room has large windows with white blinds, and a small potted plant is on the windowsill. The overall atmosphere is somber and emotional.

The Emotional Pain of Families

14 Years of Technological Advancement

Total Amount of Data




Increased Data Handling Capacity



CPU Processing Power

Number of Transistors Per Chip



Accelerated Evolution



Based on Moore's Law, the computational processing power of CPUs is described based on the number of transistors mounted on a single chip.

Source: Created by our company based on information from the websites of major chip manufacturers.

Advancement of Generative AI

Exams


GPT-4

Maintains the Ability
Comparable to Humans

National
Medical Exam

Accuracy Rate

87% (Passing: ~60%)





Medical

×



AI

A hand is shown reaching towards a bright sun, creating a lens flare effect. The background is a soft, out-of-focus bokeh of green and yellow foliage, suggesting a sunny outdoor setting. The overall mood is bright and hopeful.

Eliminate Sorrow from Illness



SoftBank
Group

"TEMPUS



"TEMPUS

Establish a JV in Japan

SB "TEMPUS

"T"EMPUS



Eric Lefkofsky

TEMPUS

Realizing Precision Medicine
through Medical Data × AI

CEO	Eric Lefkofsky (Groupon Founder)
Founded	2015
Headquarters	Chicago, USA
Valuation	\$4.5B (Listed on NASDAQ)
Revenue	\$531.8M (Fiscal Year Ending December 2023)

1 Genomic Testing



2 Medical Data Aggregation & Analysis




3 AI Insights and Therapy Selection



Offering three services

What is Cancer?


Normal Cells



Genetic
Mutation



Cancer Cells



A disease caused by genetic mutations

1. Genomic Testing

Sample Collection

Patient A

Patient B

Patient C

Lung cancer patients

1. Genomic Testing

"TEMPUS


Sample Collection

Patient A

Patient B


Patient C

Lung cancer patients




Genomic Analysis

Lung Cancer A




GGG C**G**G GCC

Lung Cancer B



GCT **T**GT GGC


Lung Cancer C



ACA **G**AG AAA

Each cancer has different mutations


1. Genomic Testing



In depth understanding of cancer characteristics


2. Medical Data Aggregation & Analysis

"TEMPUS




Combining data is key to analysis

2. Medical Data Aggregation & Analysis




Real-time integration of medical information from hospitals

3. AI Insights and Therapy Selection




Presenting optimal therapy options

3. AI Insights and Therapy Selection



Broader opportunities for patients

Patients presented with Clinical Trial Option **"TEMPUS"**



3x
U.S. Average

(Source) N. Beaubier, et al. Nat Biotechnol. 2019
Number of surveyed patients in "Next-Generation Genomic Testing + Clinical Data": 500 who underwent Tempus genomic testing
U.S. Average (reference) : Including patients who have not undergone genomic testing

Number of Cancer Patient Records

7.7
million

Number of Hospitals

2,000
hospitals


Number of Data Records

Imaging Data	1M
Pathology Data	0.97M
DNA+RNA	0.22M

The largest medical dataset in the industry

Competitive Comparison (Number of Data Types)

TEMPUS



Competitive Comparison (Data Volume)


TEMPUS

TEMPUS




7.7M

Company A




5.7M

Company B




0.65M

Company C



0.50M

Company D





0.35M

Leading
Data Volume

Academic Hospitals

Oncologists



Compelling market share in the U.S. Market



TEMPUS CEO
Eric Lefkofsky
Greeting

A wide-angle photograph of a sunset over the ocean. The sun is low on the horizon, creating a bright orange and yellow glow across the sky and reflecting on the water. The sky transitions from a pale blue at the top to a deep orange near the horizon. The ocean is dark blue with gentle waves. The text "TEMPIUS" is overlaid in the center in a large, white, sans-serif font.

"TEMPIUS

Introduction to Tempus

"TEMPUS

Healthcare data has historically been siloed and unstructured, making it difficult to deploy new technologies and deliver therapeutically relevant insights to physicians

Our Platform



Cloud Data Storage/Computing



Low-Cost Molecular Profiling
(parallel genomic sequencing)



Imaging & Language Technologies
(NLP/OCR/LLMs)


Tempus is focused on building the leading AI-enabled (Intelligent) Diagnostic platform in the world, by integrating

Data + Diagnostics




"TEMPUS ONE


tempus.com/one



Providers



Life Sciences



Data Ingestion & Acquisition

↑ ↑ ↑

State of the art high-throughput testing labs

↑ ↑ ↑

Multi-modal data from trusted healthcare institutions and associations

- ✓ DNA
- ✓ RNA
- ✓ Proteomics
- ✓ Longitudinal Clinical Data
- ✓ Clinical Imaging
- ✓ Pathology



The Cancer Genome Atlas


10,000
DNA+RNA

We operate at scale

We are connected to >65% of all Academic Medical Centers and >50% of oncologists in the U.S. are connected through our sequencing and data collection efforts.

The Cancer Genome Atlas

10,000
DNA+RNA




TEMPUS

~7,700,000
clinical records

>1,000,000
imaging records

>970,000
samples sequenced

>220,000
DNA +RNA
profiles



MOLECULAR REPORTS

Key findings and treatments for each patient, streamlined into a clinician's workflow.

Jason Jones


Born 00-00-0000 Lung adenocarcinoma

Summary Orders Order Tracking Clinical Trials

ORDER SUMMARY

xT, xF, IHC #22aaabbb - 00-00-0000 ✓ ORDER COMPLETE [View reports](#)

BIOMARKER	RESULT	TEST	THERAPIES - Diagnosis	THERAPIES - Other Indication	TRIALS
PDL1-22C3	Positive TPS: 30%, CPS:4	IHC	Pembrolizumab		
KRAS	p.G12C 14.6% VAF	xT DNA	Adagrasib Sotorasib	Drugname	2 Trials
KRAS	p.G12C 14.6% VAF	xT DNA	Adagrasib Sotorasib	Drugname	2 Trials
MUTYH	Pathogenic Potential Germline	xT DNA			1 Trial
No xG, xR potentially actionable variants were found, view report for all details					
Pertinent Negatives Not Detected	EGFR, BRAF, ALK, ROS1, RET, MET, ERBB2 (HER2)	xT DNA			
MSI	Stable	xT DNA			




CLINICAL TRIALS

Patient profiles update in real time to highlight relevant, open, and recruiting clinical trials that fit the patient's clinical and molecular profile.


TIME ON TREATMENT

Combines clinical, molecular, treatment and outcomes data to derive insights for an individual patient in the context of other similar patients.



LENS


Our Lens application provides access to robust data used to derive meaningful insights on patient populations, treatment pathways and outcomes.



SB **TEMPUS**

The joint venture allows Tempus to build clinical sequencing capabilities, organize patient data, and build a real-world data business in Japan. Tempus and the joint venture have entered into technology and data licenses to enable the joint venture's operations—the first of its kind for Tempus







GENOMICS
Diagnostic Testing

Our first product line, Genomics, focuses on delivering intelligent and personalized molecular results to physicians

96%
Tempus NGS +
Clinical Data

77%
Tempus NGS

<27%
National Average



**nature
biotechnology**

TESTS

Our tests are developed with scientific rigor.

Companion Dx

Tempus xT CDx 648 gene solid tumor cancer CDx assay*
Tempus xR IVD Whole transcriptome RNA assay

Genomics

Tempus xT 648 gene solid tumor assay
Tempus xR Whole transcriptome RNA sequencing panel
Tempus xF, xF+ 105 & 523 gene liquid biopsy cancer assays
Tempus xE Whole exome cancer assay
Tempus xG, xG+ 36 & 77 gene inherited cancer risk germline assays
Tempus xM MRD Tumor-naïve MRD assay
Tempus xM NeXT Tumor-informed WGS MRD assay
Tempus xM Monitor Tumor-naïve ctDNA detection and quantification (RUO Only)

PGx

DPYD Dihydropyrimidine dehydrogenase deficiency
UGT1A1 UDP Glucuronosyl - transferase deficiency
nP Pharmacogenomic profiling in neuropsychiatry

AI algorithms


HRD Homologous recombination deficiency
TO Tumor Origin—predicts cancer histology and site


Ancillary tests

HER2 Protein Expression**
FOLR1 FR α expression
MMR Mismatch Repair Proteins
PD-L1 PD-L1 22C3, PD-L1 28-8, PD-L1 SP142

xM

Tempus' growth to date in Genomics has been entirely within treatment selection.
With our MRD assay, we gain access to a significantly larger global market opportunity.








DATA & SERVICES
Licensing &
Analytical Tools

LICENSE DE-IDENTIFIED DATA


We provide a suite of analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies.




PRECLINICAL DISCOVERY




TARGET POPULATION OPTIMIZATION



CLINICAL TRIAL DESIGN








AI APPLICATIONS
Therapy &
Trial Matching

TRIAL MATCHING

Our algorithms look at multimodal data and make AI-enabled diagnostic recommendations only possible by virtue of our connectivity to providers.



● Signed & active ● In onboarding

6-12 months

Industry average: Activation initiation to patient consent

~14 days


Tempus: Activation initiated to activation complete

3-10 days


Tempus: Average from site activation to patient consent




- Patient reported outcomes
- Clinical data from EHR systems
- Radiology images & reports
- Germline & molecular data
- ECG & other cardiology data
- Pathology slides
- 3rd part data, claims



- ONCOLOGY**
Use molecular data to help identify primary location of tumor when its unknown, flag if a patient is HRD+
- CARDIOLOGY**
Use ECG data to screen for undiagnosed AFIB or structural heart disease
- RADIOLOGY**
Use DICOM files to flag suspected pulmonary lesions that are cancerous, measure RECIST






We started in oncology, where we have proven and scaled the model. With each new disease area, we expand upon the model by developing **Intelligent Diagnostics** to advance patient care and accelerate drug discovery and development.



最初はとても辛かったですが、非常に効果があり

SB "TEMPUS

Patients Who Receive Genomic Testing




1/30 x


In Japan, fewer patients have access to genomic testing

Patients can only undergo genomic testing after **exhausting** standard options


1 million/year



(Including patients who do not need genomic testing)




20,000/year




Most cancer patients start treatment without undergoing genomic testing

The ideal state Japan should aim for



Providing personalized medicine tailored to each individual patient

Patients Who Receive Genomic Testing



Aiming for the Same Level as the U.S.

1 Genomic Testing



2 Medical Data Aggregation & Analysis




3 AI Insights and Therapy Selection



Launching services in Japan within the year


SB **TEMPUS**

Investment
Ratio



Company Name	SB TEMPUS
Start of Operations	August 1, 2024
Capital	30 Billion Yen

U.S.



"TEMPUS

Genomic
Testing

Data Aggregation
& Analysis

AI Insights and
Therapy Selection



Japan




SB "TEMPUS

Bringing U.S.'s data-driven medical revolution to Japan

The ideal state Japan should aim for

"TEMPUS



Real-time integration of medical information from hospitals



Government



**Biotech
Ventures**



**Insurance
Company**



Pharma



Hospitals



SBTEMPUS



Clinics



**Medical Device
Manufacturers**

A strong alliance uniting the wisdom of the industry




Together with Healthcare Professionals



ASI

Artificial Super Intelligence

人類叡智の10,000倍



Medical

X



ASI



with human wisdom and ASI

Driving Down Incurable Diseases



with human wisdom and ASI

A Life Without Health Issues






with human wisdom and ASI

Staying Healthy at Any Age



Eliminate Sorrow from Illness





Information Revolution — Happiness for Everyone

